ArticleCureus2025
Percutaneous Balloon Mitral Valvuloplasty in Children and Adolescents With Juvenile Rheumatic Mitral Stenosis: Single Centre Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Rheumatic mitral stenosis (MS) in India is known to affect at a younger age, worsen rapidly, and have severe valvar and subvalvar pathology. Surgical interventions involve the risk of needing to redo surgery in the future, in addition to the acute risks of surgery itself and cardiopulmonary bypass. Therefore, percutaneous balloon mitral valvuloplasty (PBMV) has become an attractive alternative option, especially in children who rarely have any significant calcifications. Method We report our experience of PBMV in this retrospective study of 46 patients, aged 9 to 17 years (23 males, 23 females), with all being in the New York Heart Association (NYHA) class II/III. Seven patients had significant subvalvar pathology. All patients had severe pulmonary arterial hypertension (PAH). We used Accura balloons (Accura Medizintechnik GmbH, Karben, Germany) and estimated balloon size based on the height formula and used balloons 1-3 mm smaller than those derived from the formula. Results We used a smaller balloon in all the patients and had to upgrade in only seven cases. There was a significant reduction in the transmitral gradient from 19.93±6.21 mmHg to 3.54±1.1 mmHg (p<0.001) and a significant increase in the area of the mitral valve from 0.75±0.18 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.